Moving past anti-VEGF: Novel therapies for treating diabetic retinopathy

International Journal of Molecular Sciences

Volumn 17, Issue 9, 2016, Pages

  Bolinger, Mark T ^a   Antonetti, David A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Angiopoietin; Blood retinal barrier; Corticosteroid; Cytokine; Diabetic macular edema; Diabetic retinopathy; Kinin kallikrein system; Renin angiotensin system; TNF ; VEGF; Vitreomacular adhesion

Indexed keywords

ADALIMUMAB; AFLIBROCEPT; AKB 9089; AKB 9778; AKB 9875; AVORALSTAT; BCX 7353; BEVACIZUMAB; CANDASARTIN; DEXAMETHASONE; DICLOFENAC; DM 199; ECALLANTIDE; ENALAPRIL; FLUOCINOLONE ACETONIDE; ICATIBANT; INFLIXIMAB; KETOROLAC; KVD 001; LANADELUMAB; LISINOPRIL; LOSARTAN; MINOCYCLINE; NEPAFENIC; PEGAPTANIB; RANIBIZUMAB; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; KALLIKREIN; PEPTIDE; TUMOR NECROSIS FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; BLOOD RETINA BARRIER; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; GENETIC ANALYSIS; HUMAN; INCIDENCE; INFLAMMATION; KALLIKREIN KININ SYSTEM; NERVE CELL CULTURE; NONHUMAN; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; TIGHT JUNCTION; VASCULARIZATION; VISUAL ACUITY; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; PROCEDURES; TRENDS;

ADALIMUMAB; ANIMALS; BEVACIZUMAB; DIABETIC RETINOPATHY; DRUG THERAPY; HUMANS; KALLIKREINS; PEPTIDES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84987707818     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17091498     Document Type: Review

References (178)

1. Fong, D.S.; Aiello, L.; Gardner, T.W.; King, G.L.; Blankenship, G.; Cavallerano, J.D.; Ferris, F.L., 3rd; Klein, R. Retinopathy in Diabetes. Diabetes Care 2003, 26, s84–s87. [CrossRef]
2. Aiello, L.P.; Gardner, T.W.; King, G.L.; Blankenship, G.; Cavallerano, J.D.; Ferris, F.L., 3rd; Klein, R. Diabetic retinopathy. Diabetes Care 1998, 21, 143–156. [CrossRef] [PubMed]
3. Centers for Disease Control and Prevention. Prevention, Blindness caused by diabetes—Massachusetts, 1987–1994. Morb. Mortal. Wkly. Rep. 1996, 45, 937–941.
4. Javitt, J.C.; Aiello, L.P.; Chiang, Y.; Ferris, F.L., 3rd; Canner, J.K.; Greenfield, S. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994, 17, 909–917. [CrossRef] [PubMed]
5. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016, 387, 1513–1530.
6. Yau, J.W.; Rogers, S.L.; Kawasaki, R.; Lamoureux, E.L.; Kowalski, J.W.; Bek, T.; Chen, S.J.; Dekker, J.M.; Fletcher, A.; Grauslund, J., et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012, 35, 556–564. [CrossRef] [PubMed]
7. Boyle, J.P.; Thompson, T.J.; Gregg, E.W.; Barker, L.E.; Williamson, D.F. Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metr. 2010, 8. [CrossRef] [PubMed]
8. Frey, T.; Antonetti, D.A. Alterations to the blood-retinal barrier in diabetes: Cytokines and reactive oxygen species. Antioxid. Redox Signal. 2011, 15, 1271–1284. [CrossRef] [PubMed]
9. Winton-Brown, T.T.; Ting, A.; Mocellin, R.; Velakoulis, D.; Gaillard, F. Distinguishing neuroimaging features in patients presenting with visual hallucinations. Am. J. Neuroradiol. 2016, 37, 774–781. [CrossRef] [PubMed]
10. Provis, J.M. Development of the primate retinal vasculature. Progress Retin. Eye Res. 2001, 20, 799–821. [CrossRef]
11. Zhou, R.; Caspi, R.R. Ocular immune privilege. F1000 Biol. Rep. 2010, 2. [CrossRef] [PubMed]
12. Antonetti, D.A.; Klein, R.; Gardner, T.W. Diabetic retinopathy. N. Engl. J. Med. 2012, 366, 1227–1239. [CrossRef] [PubMed]
13. Maines, L.W.; Antonetti, D.A.; Wolpert, E.B.; Smith, C.D. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 2005, 49, 610–617. [CrossRef] [PubMed]
14. Zhou, Y.; Wang, Y.; Tischfield, M.; Williams, J.; Smallwood, P.M.; Rattner, A.; Taketo, M.M.; Nathans, J. Canonical WNT signaling components in vascular development and barrier formation. J. Clin. Investig. 2014, 124, 3825–3846. [CrossRef] [PubMed]
15. Armulik, A.; Genove, G.; Mae, M.; Nisancioglu, M.H.; Wallgard, E.; Niaudet, C.; He, L.; Norlin, J.; Lindblom, P.; Strittmatter, K., et al. Pericytes regulate the blood-brain barrier. Nature 2010, 468, 557–561. [CrossRef] [PubMed]
16. Antonetti, D.A.; Van Guilder, H.D.; Lin, C.M. Vascular permeability in diabetic retinopahty. In Diabetic Retinopathy; Duh, E.J., Ed.; Humana Press: Totwa, NJ, USA, 2008; pp. 333–352.
17. Abcouwer, S.F.; Gardner, T.W. Diabetic retinopathy: Loss of neuroretinal adaptation to the diabetic metabolic environment. Ann. N. Y. Acad. Sci. 2014, 1311, 174–190. [CrossRef] [PubMed]
18. Stem, M.S.; Gardner, T.W. Neurodegeneration in the pathogenesis of diabetic retinopathy: Molecular mechanisms and therapeutic implications. Curr. Med. Chem. 2013, 20, 3241–3250. [CrossRef] [PubMed]
19. Du, J.; Cleghorn, W.; Contreras, L.; Linton, J.D.; Chan, G.C.; Chertov, A.O.; Saheki, T.; Govindaraju, V.; Sadilek, M.; Satrustegui, J., et al. Cytosolic reducing power preserves glutamate in retina. Proc. Natl. Acad. Sci. USA 2013, 110, 18501–18506. [CrossRef] [PubMed]
20. Buttery, R.G.; Hinrichsen, C.F.; Weller, W.L.; Haight, J.R. How thick should a retina be? A comparative study of mammalian species with and without intraretinal vasculature. Vis. Res. 1991, 31, 169–187. [CrossRef]
21. Schneeberger, E.E.; Lynch, R.D. The tight junction: A multifunctional complex. Am. J. Physiol. Cell Physiol. 2004, 286, C1213–C1228. [CrossRef] [PubMed]
22. Fanning, A.S.; Jameson, B.J.; Jesaitis, L.A.; Anderson, J.M. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J. Biol. Chem. 1998, 273, 29745–29753. [CrossRef] [PubMed]
23. Antonetti, D.A.; Barber, A.J.; Khin, S.; Lieth, E.; Tarbell, J.M.; Gardner, T.W. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: Vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 1998, 47, 1953–1959. [CrossRef] [PubMed]
24. Hirase, T.; Staddon, J.M.; Saitou, M.; Ando-Akatsuka, Y.; Itoh, M.; Furuse, M.; Fujimoto, K.; Tsukita, S.; Rubin, L.L. Occludin as a possible determinant of tight junction permeability in endothelial cells. J. Cell Sci. 1997, 110 Pt 14, 1603–1613. [PubMed]
25. Phillips, B.E.; Antonetti, D.A. Blood-retinal barrier, retinal vascular leakage and macular edema. In Retinal Vascular Diseases; Joussen, A.M., Gardner, T.W., Kirshhof, B., Ryan, S.J., Eds.; Springer-Verlag: Berlin, Germany, 2007; pp. 139–147.
26. Katsuno, T.; Umeda, K.; Matsui, T.; Hata, M.; Tamura, A.; Itoh, M.; Takeuchi, K.; Fujimori, T.; Nabeshima, Y.; Noda, T., et al. Deficiency of zonula occludens-1 causes embryonic lethal phenotype associated with defected yolk sac angiogenesis and apoptosis of embryonic cells. Mol. Biol. Cell 2008, 19, 2465–2475. [CrossRef] [PubMed]
27. Xu, J.; Kausalya, P.J.; Phua, D.C.; Ali, S.M.; Hossain, Z.; Hunziker, W. Early embryonic lethality of mice lacking ZO-2, but Not ZO-3, reveals critical and nonredundant roles for individual zonula occludens proteins in mammalian development. Mol. Cell. Biol. 2008, 28, 1669–1678. [CrossRef] [PubMed]
28. Furuse, M.; Hata, M.; Furuse, K.; Yoshida, Y.; Haratake, A.; Sugitani, Y.; Noda, T.; Kubo, A.; Tsukita, S. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: A lesson from claudin-1-deficient mice. J. Cell Biol. 2002, 156, 1099–1111. [CrossRef] [PubMed]
29. Muto, S.; Hata, M.; Taniguchi, J.; Tsuruoka, S.; Moriwaki, K.; Saitou, M.; Furuse, K.; Sasaki, H.; Fujimura, A.; Imai, M., et al. Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc. Natl. Acad. Sci. USA. 2010, 107, 8011–8016. [CrossRef] [PubMed]
30. Breiderhoff, T.; Himmerkus, N.; Stuiver, M.; Mutig, K.; Will, C.; Meij, I.C.; Bachmann, S.; Bleich, M.; Willnow, T.E.; Muller, D. Deletion of claudin-10 (Cldn10) in the thick ascending limb impairs paracellular sodium permeability and leads to hypermagnesemia and nephrocalcinosis. Proc. Natl. Acad. Sci. USA 2012, 109, 14241–14246. [CrossRef] [PubMed]
31. Nitta, T.; Hata, M.; Gotoh, S.; Seo, Y.; Sasaki, H.; Hashimoto, N.; Furuse, M.; Tsukita, S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 2003, 161, 653–660. [CrossRef] [PubMed]
32. Li, G.; Flodby, P.; Luo, J.; Kage, H.; Sipos, A.; Gao, D.; Ji, Y.; Beard, L.L.; Marconett, C.N.; DeMaio, L., et al. Knockout mice reveal key roles for claudin 18 in alveolar barrier properties and fluid homeostasis. Am. J. Respir. Cell Mol. Biol. 2014, 51, 210–222. [CrossRef] [PubMed]
33. Saitou, M.; Furuse, M.; Sasaki, H.; Schulzke, J.D.; Fromm, M.; Takano, H.; Noda, T.; Tsukita, S. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol. Biol. Cell 2000, 11, 4131–4142. [CrossRef] [PubMed]
34. Schulzke, J.D.; Gitter, A.H.; Mankertz, J.; Spiegel, S.; Seidler, U.; Amasheh, S.; Saitou, M.; Tsukita, S.; Fromm, M. Epithelial transport and barrier function in occludin-deficient mice. Biochim. Biophys. Acta 2005, 1669, 34–42. [CrossRef] [PubMed]
35. Murakami, T.; Felinski, E.A.; Antonetti, D.A. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J. Biol. Chem. 2009, 284, 21036–21046. [CrossRef] [PubMed]
36. Wessel, F.; Winderlich, M.; Holm, M.; Frye, M.; Rivera-Galdos, R.; Vockel, M.; Linnepe, R.; Ipe, U.; Stadtmann, A.; Zarbock, A., et al. Leukocyte extravasation and vascular permeabilitity are each controlled in vivo by different tyrosine residues of VE-cadherin. Nat. Immunol. 2014, 15, 223–230. [CrossRef] [PubMed]
37. Williams, R.; Airey, M.; Baxter, H.; Forrester, J.; Kennedy-Martin, T.; Girach, A. Epidemiology of diabetic retinopathy and macular oedema: A systematic review. Eye 2004, 18, 963–983. [CrossRef] [PubMed]
38. Ivanova, T.; Jalil, A.; Antoniou, Y.; Bishop, P.N.; Vallejo-Garcia, J.L.; Patton, N. Vitrectomy for primary symptomatic vitreous opacities: An evidence-based review. Eye 2016, 30, 645–655. [CrossRef] [PubMed]
39. Ali, F.A. A review of diabetic macular edema. Dig. J. Ophthalmol. 1997, 3.
40. Klein, R.; Knudtson, M.D.; Lee, K.E.; Gangnon, R.; Klein, B.E. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: The twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009, 116, 497–503. [CrossRef] [PubMed]
41. Klein, R.; Moss, S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch. Intern. Med. 1995, 155, 745–754. [CrossRef] [PubMed]
42. Romero-Aroca, P.; Baget-Bernaldiz, M.; Fernandez-Ballart, J.; Plana-Gil, N.; Soler-Lluis, N.; Mendez-Marin, I.; Bautista-Perez, A. Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes. Diabetes Res. Clin. Pract. 2011, 94, 126–132. [CrossRef] [PubMed]
43. Diabetic Retinopathy Clinical Research Network; Browning, D.J.; Glassman, A.R.; Aiello, L.P.; Beck, R.W.; Brown, D.W.; Fong, D.S.; Bressler, N.M.; Danis, R.P.; Kinyoun, J.L., et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007, 114, 525–536. [PubMed]
44. Patelli, F.; Fasolino, G.; Radice, P.; Russo, S.; Zumbo, G.; di Tizio, F.M.; Frisone, G.; Marchi, S. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina 2005, 25, 840–845. [CrossRef] [PubMed]
45. Gardner, T.W.; Larsen, M.; Girach, A.; Zhi, X. Diabetic macular oedema and visual loss: Relationship to location, severity and duration. Acta Ophthalmol. 2009, 87, 709–713. [CrossRef] [PubMed]
46. Sander, B.; Thornit, D.N.; Colmorn, L.; Strom, C.; Girach, A.; Hubbard, L.D.; Lund-Andersen, H.; Larsen, M. Progression of diabetic macular edema: Correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter. Investig. Ophthalmol. Vis. Sci. 2007, 48, 3983–3987. [CrossRef] [PubMed]
47. Lee, R.; Wong, T.Y.; Sabanayagam, C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015, 2. [CrossRef] [PubMed]
48. Meyer-Schwickerath, G. Light coagulation; a method for treatment and prevention of the retinal detachment. Albrecht Graefes Arch. Ophthalmol. 1954, 156, 2–34. [CrossRef]
49. The Early Treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 3. Int. Ophthalmol. Clin. 1987, 27, 254–264.
50. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981, 88, 583–600.
51. Fong, D.S.; Girach, A.; Boney, A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: A literature review. Retina 2007, 27, 816–824. [CrossRef] [PubMed]
52. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein, H.C.; Miller, M.E.; Byington, R.P.; Goff, D.C., Jr.; Bigger, J.T.; Buse, J.B.; Cushman,W.C.; Genuth, S.; Ismail-Beigi, F., et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008, 358, 2545–2559. [PubMed]
53. Chew, E.Y.; Davis, M.D.; Danis, R.P.; Lovato, J.F.; Perdue, L.H.; Greven, C.; Genuth, S.; Goff, D.C.; Leiter, L.A.; Ismail-Beigi, F., et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology 2014, 121, 2443–2451. [CrossRef] [PubMed]
54. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998, 352, 837–853.
55. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329, 978–986.
56. Nathan, D.M.; Cleary, P.A.; Backlund, J.Y.; Genuth, S.M.; Lachin, J.M.; Orchard, T.J.; Raskin, P.; Zinman, B. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005, 353, 2643–2653. [PubMed]
57. Keck, P.J.; Hauser, S.D.; Krivi, G.; Sanzo, K.; Warren, T.; Feder, J.; Connolly, D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246, 1309–1312. [CrossRef] [PubMed]
58. Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246, 1306–1309. [CrossRef] [PubMed]
59. Miller, J.W.; Adamis, A.P.; Shima, D.T.; D’Amore, P.A.; Moulton, R.S.; O’Reilly, M.S.; Folkman, J.; Dvorak, H.F.; Brown, L.F.; Berse, B., et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 1994, 145, 574–584. [CrossRef] [PubMed]
60. Aiello, L.P.; Avery, R.L.; Arrigg, P.G.; Keyt, B.A.; Jampel, H.D.; Shah, S.T.; Pasquale, L.R.; Thieme, H.; Iwamoto, M.A.; Park, J.E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 1994, 331, 1480–1487. [CrossRef] [PubMed]
61. Argaw, A.T.; Gurfein, B.T.; Zhang, Y.; Zameer, A.; John, G.R. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc. Natl. Acad. Sci. USA 2009, 106, 1977–1982. [CrossRef] [PubMed]
62. Simo, R.; Sundstrom, J.M.; Antonetti, D.A. Ocular Anti-VEGF therapy for diabetic retinopathy: The role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 2014, 37, 893–899. [CrossRef] [PubMed]
63. Stefanini, F.R.; Badaro, E.; Falabella, P.; Koss, M.; Farah, M.E.; Maia, M. Anti-VEGF for the management of diabetic macular edema. J. Immunol. Res. 2014, 2014, 632307. [CrossRef] [PubMed]
64. Osaadon, P.; Fagan, X.J.; Lifshitz, T.; Levy, J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye 2014, 28, 510–520. [CrossRef] [PubMed]
65. Nguyen, Q.D.; Brown, D.M.; Marcus, D.M.; Boyer, D.S.; Patel, S.; Feiner, L.; Gibson, A.; Sy, J.; Rundle, A.C.; Hopkins, J.J., et al. Ranibizumab for diabetic macular edema; results from 2 phase III randomized trials; RISE and RIDE. Ophthalmology 2012, 119, 789–801. [CrossRef] [PubMed]
66. Writing Committee for the Diabetic Retinopathy Clinical Research Network; Gross, J.G.; Glassman, A.R.; Jampol, L.M.; Inusah, S.; Aiello, L.P.; Antoszyk, A.N.; Baker, C.W.; Berger, B.B.; Bressler, N.M., et al. Panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA 2015, 314, 2137–2146. [PubMed]
67. Group C.R.; Martin, D.F.; Maguire, M.G.; Ying, G.S.; Grunwald, J.E.; Fine, S.L.; Jaffe, G.J. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2011, 364, 1897–1908.
68. Dabir, S.S.; Das, D.; Nallathambi, J.; Mangalesh, S.; Yadav, N.K.; Schouten, J.S. Differential systemic gene expression profile in patients with diabetic macular edema: Responders versus nonresponders to standard treatment. Indian J. Ophthalmol. 2014, 62, 66–73. [CrossRef] [PubMed]
69. Simo-Servat, O.; Hernandez, C.; Simo, R. Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy. Mediat. Inflamm. 2012, 2012, 872978. [CrossRef] [PubMed]
70. Semeraro, F.; Cancarini, A.; dell’Omo, R.; Rezzola, S.; Romano, M.R.; Costagliola, C. Diabetic Retinopathy: Vascular and Inflammatory Disease. J. Diabetes Res. 2015, 2015. [CrossRef] [PubMed]
71. Kern, T.S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 2007. [CrossRef] [PubMed]
72. Kowluru, R.A.; Odenbach, S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br. J. Ophthalmol. 2004, 88, 1343–1347. [CrossRef] [PubMed]
73. Kahn, S.E.; Hull, R.L.; Utzschneider, K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444, 840–846. [CrossRef] [PubMed]
74. Doganay, S.; Evereklioglu, C.; Er, H.; Turkoz, Y.; Sevinc, A.; Mehmet, N.; Savli, H. Comparison of serum NO, TNF-α, IL-β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 2002, 16, 163–170. [CrossRef] [PubMed]
75. Bamforth, S.D.; Lightman, S.; Greenwood, J. The effect of TNF-α and IL-6 on the permeability of the rat blood-retinal barrier in vivo. Acta Neuropathol. 1996, 91, 624–632. [CrossRef] [PubMed]
76. Aveleira, C.A.; Lin, C.M.; Abcouwer, S.F.; Ambrosio, A.F.; Antonetti, D.A. TNF-alpha signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 2010, 59, 2872–2882. [CrossRef] [PubMed]
77. Huang, H.; Zhao, N.; Xu, X.; Xu, Y.; Li, S.; Zhang, J.; Yang, P. Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells. Cell Prolif. 2011, 44, 420–427. [CrossRef] [PubMed]
78. Sfikakis, P.P.; Grigoropoulos, V.; Emfietzoglou, I.; Theodossiadis, G.; Tentolouris, N.; Delicha, E.; Katsiari, C.; Alexiadou, K.; Hatziagelaki, E.; Theodossiadis, P.G. Infliximab for diabetic macular edema refractory to laser photocoagulation: A randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010, 33, 1523–1528. [CrossRef] [PubMed]
79. Wu, L.; Hernandez-Bogantes, E.; Roca, J.A.; Arevalo, J.F.; Barraza, K.; Lasave, A.F. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: A pilot study from the Pan-American Collaborative Retina Study Group. Retina 2011, 31, 298–303. [CrossRef] [PubMed]
80. Giganti, M.; Beer, P.M.; Lemanski, N.; Hartman, C.; Schartman, J.; Falk, N. Adverse events after intravitreal infliximab (Remicade). Retina 2010, 30, 71–80. [CrossRef] [PubMed]
81. Levy-Clarke, G.; Jabs, D.A.; Read, R.W.; Rosenbaum, J.T.; Vitale, A.; van Gelder, R.N. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014, 121, 785–796. [CrossRef]
82. McLean, J.M. Use of ACTH and cortisone. Trans. Am. Ophthalmol. Soc. 1950, 48, 293–296.
83. Jonas, J.B.; Jonas, R.A.; Neumaier, M.; Findeisen, P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina 2012, 32, 2150–2157. [CrossRef]
84. Caceres-del-Carpio, J.; Costa, R.D.; Haider, A.; Narayanan, R.; Kuppermann, B.D. Corticosteroids: Triamcinolone, Dexamethasone and Fluocinolone. Dev. Ophthalmol. 2016, 55, 221–231.
85. Pagano, G.; Bruno, A.; Cavallo-Perin, P.; Cesco, L.; Imbimbo, B. Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Prednisone, deflazacort, and betamethasone. Arch. Intern. Med. 1989, 149, 1098–1101. [CrossRef] [PubMed]
86. Saag, K.G. Glucocorticoid-induced osteoporosis. Endocrinol. Metab. Clin. N. Am. 2003, 32, 135–157. [CrossRef]
87. Francois, J. Cortisone et tension oculaire (in French). Ann. d’Oculist 1954, 187, 805.
88. Diabetic Retinopathy Clinical Research Network; Elman, M.J.; Aiello, L.P.; Beck, R.W.; Bressler, N.M.; Bressler, S.B.; Edwards, A.R.; Ferris, F.L., 3rd; Friedman, S.M.; Glassman, A.R., et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117, 1064–1077. [CrossRef] [PubMed]
89. Jonas, J.B.; Kreissig, I.; Degenring, R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br. J. Ophthalmol. 2003, 87, 24–27. [CrossRef] [PubMed]
90. Gillies, M.C.; Kuzniarz, M.; Craig, J.; Ball, M.; Luo, W.; Simpson, J.M. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005, 112, 139–143. [CrossRef] [PubMed]
91. Abcouwer, S.F. Angiogenic factors and cytokines in diabetic retinopathy. J. Clin. Cell. Immunol. 2013, S1, 1–12. [CrossRef]
92. Chang-Lin, J.E.; Attar, M.; Acheampong, A.A.; Robinson, M.R.; Whitcup, S.M.; Kuppermann, B.D.; Welty, D. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Investig. Ophthalmol. Vis. Sci. 2011, 52, 80–86. [CrossRef] [PubMed]
93. Boyer, D.S.; Yoon, Y.H.; Belfort, R., Jr.; Bandello, F.; Maturi, R.K.; Augustin, A.J.; Li, X.Y.; Cui, H.; Hashad, Y.; Whitcup, S.M., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014, 121, 1904–1914. [CrossRef] [PubMed]
94. Zhioua, I.; Semoun, O.; Lalloum, F.; Souied, E.H. Intravitreal Dexamethasone Implant in Patients with Ranibizumab Persistent Diabetic Macular Edema. Retina 2015, 35, 1429–1435. [CrossRef] [PubMed]
95. Lazic, R.; Lukic, M.; Boras, I.; Draca, N.; Vlasic, M.; Gabric, N.; Tomic, Z. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2014, 34, 719–724. [CrossRef] [PubMed]
96. Arcinue, C.A.; Ceron, O.M.; Foster, C.S. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J. Ocul. Pharmacol. Ther. 2013, 29, 501–507. [CrossRef] [PubMed]
97. Schwartz, S.G.; Flynn, H.W., Jr. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr. Pharm. Biotechnol. 2011, 12, 347–351. [CrossRef] [PubMed]
98. Pearson, P.A.; Comstock, T.L.; Ip, M.; Callanan, D.; Morse, L.S.; Ashton, P.; Levy, B.; Mann, E.S.; Eliott, D. Fluocinolone acetonide intravitreal implant for diabetic macular edema: A 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011, 118, 1580–1587. [CrossRef] [PubMed]
99. Campochiaro, P.A.; Nguyen, Q.D.; Hafiz, G.; Bloom, S.; Brown, D.M.; Busquets, M.; Ciulla, T.; Feiner, L.; Sabates, N.; Billman, K., et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology 2013, 120, 583–587. [CrossRef] [PubMed]
100. Campochiaro, P.A.; Hafiz, G.; Shah, S.M.; Bloom, S.; Brown, D.M.; Busquets, M.; Ciulla, T.; Feiner, L.; Sabates, N.; Billman, K., et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010, 117, 1393–1399. [CrossRef] [PubMed]
101. Kita, T.; Clermont, A.C.; Murugesan, N.; Zhou, Q.; Fujisawa, K.; Ishibashi, T.; Aiello, L.P.; Feener, E.P. Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema. Diabetes 2015, 64, 3588–3599. [CrossRef] [PubMed]
102. Stone, O.A.; Richer, C.; Emanueli, C.; van Weel, V.; Quax, P.H.; Katare, R.; Kraenkel, N.; Campagnolo, P.; Barcelos, L.S.; Siragusa, M., et al. Critical role of tissue kallikrein in vessel formation and maturation: Implications for therapeutic revascularization. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 657–664. [CrossRef] [PubMed]
103. Maas, C.; Govers-Riemslag, J.W.; Bouma, B.; Schiks, B.; Hazenberg, B.P.; Lokhorst, H.M.; Hammarstrom, P.; ten Cate, H.; de Groot, P.G.; Bouma, B.N., et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J. Clin. Investig. 2008, 118, 3208–3218. [CrossRef] [PubMed]
104. Catanzaro, O.L.; Dziubecki, D.; Obregon, P.; Rodriguez, R.R.; Sirois, P. Antidiabetic efficacy of bradykinin antagonist R-954 on glucose tolerance test in diabetic type 1 mice. Neuropeptides 2010, 44, 187–189. [CrossRef] [PubMed]
105. Leeb-Lundberg, L.M.; Marceau, F.; Muller-Esterl, W.; Pettibone, D.J.; Zuraw, B.L. International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 2005, 57, 27–77. [CrossRef] [PubMed]
106. Chao, J.; Yin, H.; Gao, L.; Hagiwara, M.; Shen, B.; Yang, Z.R.; Chao, L. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension 2008, 52, 715–720. [CrossRef] [PubMed]
107. Abdouh, M.; Talbot, S.; Couture, R.; Hassessian, H.M. Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B1 and B2 receptors. Br. J. Pharmacol. 2008, 154, 136–143. [CrossRef] [PubMed]
108. Mejia, A.J.; Matus, C.E.; Pavicic, F.; Concha, M.; Ehrenfeld, P.; Figueroa, C.D. Intracellular signaling pathways involved in the release of IL-4 and VEGF from human keratinocytes by activation of kinin B1 receptor: Functional relevance to angiogenesis. Arch. Dermatol. Res. 2015, 307, 803–817. [CrossRef] [PubMed]
109. Bhoola, K.D.; Figueroa, C.D.; Worthy, K. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol. Rev. 1992, 44, 1–80. [PubMed]
110. Bhat, M.; Pouliot, M.; Couture, R.; Vaucher, E. The kallikrein-kinin system in diabetic retinopathy. Prog. Drug Res. 2014, 69, 111–143. [PubMed]
111. Abdouh, M.; Khanjari, A.; Abdelazziz, N.; Ongali, B.; Couture, R.; Hassessian, H.M. Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat. Br. J. Pharmacol. 2003, 140, 33–40. [CrossRef] [PubMed]
112. Ni, A.; Yin, H.; Agata, J.; Yang, Z.; Chao, L.; Chao, J. Overexpression of kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and susceptibility to inflammation. J. Biol. Chem. 2003, 278, 219–225. [CrossRef] [PubMed]
113. Pesquero, J.B.; Araujo, R.C.; Heppenstall, P.A.; Stucky, C.L.; Silva, J.A., Jr.; Walther, T.; Oliveira, S.M.; Pesquero, J.L.; Paiva, A.C.; Calixto, J.B., et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc. Natl. Acad. Sci. USA 2000, 97, 8140–8145. [CrossRef] [PubMed]
114. Kedzierska, K.; Ciechanowski, K.; Golembiewska, E.; Safranow, K.; Ciechanowicz, A.; Domanski, L.; Myslak, M.; Rozanski, J. Plasma prekallikrein as a risk factor for diabetic retinopathy. Arch. Med. Res. 2005, 36, 539–543. [CrossRef] [PubMed]
115. Sharma, J.N.; Al-Shoumer, K.A.; Matar, K.M.; Al-Gharee, H.Y.; Madathil, N.V. Bradykinin-forming components in Kuwaiti patients with type 2 diabetes. Int. J. Immunopathol. Pharmacol. 2013, 26, 699–705. [PubMed]
116. Phipps, J.A.; Clermont, A.C.; Sinha, S.; Chilcote, T.J.; Bursell, S.E.; Feener, E.P. Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension 2009, 53, 175–181. [CrossRef] [PubMed]
117. Gao, B.; Clermont, A.; Rook, S.; Fonda, S.J.; Srinivasan, V.J.; Wojtkowski, M.; Fujimoto, J.G.; Avery, R.L.; Arrigg, P.G.; Bursell, S., et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 2007, 13, 181–188. [CrossRef] [PubMed]
118. Zuraw, B.L.; Banerji, A.; Bernstein, J.A.; Busse, P.J.; Christiansen, S.C.; Davis-Lorton, M.; Frank, M.M.; Li, H.H.; Lumry, W.R.; Riedl, M., et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J. Allergy Clin. Immunol. Pract. 2013, 1, 458–467. [CrossRef] [PubMed]
119. Chyung, Y.; Vince, B.; Iarrobino, R.; Sexton, D.; Kenniston, J.; Faucette, R.; TenHoor, C.; Stolz, L.E.; Stevens, C.; Biedenkapp, J., et al. A phase 1 study investigating DX-2930 in healthy subjects. Ann. Allergy Asthma Immunol. 2014, 113, 460–466. [CrossRef] [PubMed]
120. Wegman-Ostrosky, T.; Soto-Reyes, E.; Vidal-Millan, S.; Sanchez-Corona, J. The renin-angiotensin system meets the hallmarks of cancer. J. Renin Angiotensin Aldosterone Syst. 2015, 16, 227–233. [CrossRef] [PubMed]
121. Vincent, F.; Bonnin, P.; Clemessy, M.; Contreres, J.O.; Lamande, N.; Gasc, J.M.; Vilar, J.; Hainaud, P.; Tobelem, G.; Corvol, P., et al. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res. 2009, 69, 2853–2860. [CrossRef] [PubMed]
122. Sjolie, A.K.; Klein, R.; Porta, M.; Orchard, T.; Fuller, J.; Parving, H.H.; Bilous, R.; Aldington, S.; Chaturvedi, N. Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme. Diabet. Med. 2011, 28, 345–351. [CrossRef] [PubMed]
123. Mauer, M.; Zinman, B.; Gardiner, R.; Suissa, S.; Sinaiko, A.; Strand, T.; Drummond, K.; Donnelly, S.; Goodyer, P.; Gubler, M.C., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 2009, 361, 40–51. [CrossRef] [PubMed]
124. Bader, M. Kallikrein-kinin system in neovascularization. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 617–619. [CrossRef] [PubMed]
125. Ismael, M.A.; Talbot, S.; Carbonneau, C.L.; Beausejour, C.M.; Couture, R. Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance. Eur. J. Pharmacol. 2008, 589, 66–72. [CrossRef] [PubMed]
126. Murakami, T. Kallikrein-Kinin System: An Emerging Competitor or Collaborator for VEGF in Diabetic Macular Edema? Diabetes 2015, 64, 3350–3352. [CrossRef] [PubMed]
127. Bas, M.; Greve, J.; Stelter, K.; Havel, M.; Strassen, U.; Rotter, N.; Veit, J.; Schossow, B.; Hapfelmeier, A.; Kehl, V., et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N. Engl. J. Med. 2015, 372, 418–425. [CrossRef] [PubMed]
128. Joseph, K.; Tholanikunnel, T.E.; Kaplan, A.P. In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme. J. Renin Angiotensin Aldosterone Syst. 2015, 16, 321–327. [CrossRef] [PubMed]
129. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317, 703–713.
130. Chaturvedi, N.; Sjolie, A.K.; Stephenson, J.M.; Abrahamian, H.; Keipes, M.; Castellarin, A.; Rogulja-Pepeonik, Z.; Fuller, J.H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998, 351, 28–31. [CrossRef]
131. Wang, B.; Wang, F.; Zhang, Y.; Zhao, S.H.; Zhao, W.J.; Yan, S.L.; Wang, Y.G. Effects of RAS inhibitors on diabetic retinopathy: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015, 3, 263–274. [CrossRef]
132. Yacyshyn, O.K.; Lai, P.F.; Forse, K.; Teichert-Kuliszewska, K.; Jurasz, P.; Stewart, D.J. Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells. Angiogenesis 2009, 12, 25–33. [CrossRef] [PubMed]
133. Davis, S.; Aldrich, T.H.; Jones, P.F.; Acheson, A.; Compton, D.L.; Jain, V.; Ryan, T.E.; Bruno, J.; Radziejewski, C.; Maisonpierre, P.C., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87, 1161–1169. [CrossRef]
134. Gamble, J.R.; Drew, J.; Trezise, L.; Underwood, A.; Parsons, M.; Kasminkas, L.; Rudge, J.; Yancopoulos, G.; Vadas, M.A. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ. Res. 2000, 87, 603–607. [CrossRef] [PubMed]
135. Joussen, A.M.; Poulaki, V.; Tsujikawa, A.; Qin, W.; Qaum, T.; Xu, Q.; Moromizato, Y.; Bursell, S.E.; Wiegand, S.J.; Rudge, J., et al. Suppression of diabetic retinopathy with angiopoietin-1. Am. J. Pathol. 2002, 160, 1683–1693. [CrossRef]
136. Holash, J.; Maisonpierre, P.C.; Compton, D.; Boland, P.; Alexander, C.R.; Zagzag, D.; Yancopoulos, G.D.; Wiegand, S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284, 1994–1998. [CrossRef] [PubMed]
137. Scharpfenecker, M.; Fiedler, U.; Reiss, Y.; Augustin, H.G. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J. Cell Sci. 2005, 118, 771–780. [CrossRef] [PubMed]
138. Watanabe, D.; Suzuma, K.; Suzuma, I.; Ohashi, H.; Ojima, T.; Kurimoto, M.; Murakami, T.; Kimura, T.; Takagi, H. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 2005, 139, 476–481. [CrossRef] [PubMed]
139. Tuuminen, R.; Haukka, J.; Loukovaara, S. Poor glycemic control associates with high intravitreal angiopoietin-2 levels in patients with diabetic retinopathy. Acta Ophthalmol. 2015, 93, e515–e516. [CrossRef] [PubMed]
140. Rangasamy, S.; McGuire, P.G.; Das, A. Diabetic retinopathy and inflammation: Novel therapeutic targets. Middle East Afr. J. Ophthalmol. 2012, 19, 52–59. [PubMed]
141. Tang, J.; Kern, T.S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011, 30, 343–358. [CrossRef] [PubMed]
142. Early Treatment Diabetic Retinopathy Study Research Group. Effects of Aspirin Treatment on Diabetic Retinopathy. ETDRS report number 8. Ophthalmology 1991, 98, 757–765.
143. Esgin, H.; Samut, H.S. Topical ketorolac 0.5% for ocular pain relief during scatter laser photocoagulation with 532 nm green laser. J. Ocul. Pharmacol. Ther. 2006, 22, 460–464. [CrossRef] [PubMed]
144. Ngo, L.L.; Ward, K.K.; Mody, S.K. Ketorolac for Pain Control With Intrauterine Device Placement: A Randomized Controlled Trial. Obstet. Gynecol. 2015, 126, 29–36. [CrossRef] [PubMed]
145. Siribumrungwong, K.; Cheewakidakarn, J.; Tangtrakulwanich, B.; Nimmaanrat, S. Comparing parecoxib and ketorolac as preemptive analgesia in patients undergoing posterior lumbar spinal fusion: A prospective randomized double-blinded placebo-controlled trial. BMC Musculoskelet. Disord. 2015, 16, 59. [CrossRef] [PubMed]
146. Patricio, J.P.; Barbosa, J.P.; Ramos, R.M.; Antunes, N.F.; de Melo, P.C. Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: Implications for clinical practice. Clin. Drug Investig. 2013, 33, 167–183. [CrossRef] [PubMed]
147. Maldonado, R.M.; Vianna, R.N.; Cardoso, G.P.; de Magalhaes, A.V.; Burnier, M.N., Jr. Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Curr. Eye Res. 2011, 36, 768–773. [CrossRef] [PubMed]
148. Schoenberger, S.D.; Kim, S.J.; Shah, R.; Sheng, J.; Cherney, E. Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. JAMA Ophthalmol. 2014, 132, 32–37. [CrossRef] [PubMed]
149. Friedman, S.M.; Almukhtar, T.H.; Baker, C.W.; Glassman, A.R.; Elman, M.J.; Bressler, N.M.; Maker, M.P.; Jampol, L.M.; Melia, M.; Diabetic retinopathy clinical research network. Topical nepafenec in eyes with noncentral diabetic macular edema. Retina 2015, 35, 944–956. [CrossRef] [PubMed]
150. Kulik, A.; Bykov, K.; Choudhry, N.K.; Bateman, B.T. Non-steroidal anti-inflammatory drug administration after coronary artery bypass surgery: Utilization persists despite the boxed warning. Pharmacoepidemiol. Drug Saf. 2015, 24, 647–653. [CrossRef] [PubMed]
151. McCormack, P.L. Ketorolac 0.45% ophthalmic solution. Drugs Aging 2011, 28, 583–589. [CrossRef] [PubMed]
152. Solomon, K.D.; Cheetham, J.K.; DeGryse, R.; Brint, S.F.; Rosenthal, A. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001, 108, 331–337. [CrossRef]
153. Krady, J.K.; Basu, A.; Allen, C.M.; Xu, Y.; LaNoue, K.F.; Gardner, T.W.; Levison, S.W. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005, 54, 1559–1565. [CrossRef] [PubMed]
154. Cukras, C.A.; Petrou, P.; Chew, E.Y.; Meyerle, C.B.; Wong,W.T. Oral minocycline for the treatment of diabetic macular edema (DME): Results of a phase I/II clinical study. Investig. Ophthalmol. Vis. Sci. 2012, 53, 3865–3874. [CrossRef] [PubMed]
155. Wu, Y.; Chen, Y.; Wu, Q.; Jia, L.; Du, X. Minocycline inhibits PARP1 expression and decreases apoptosis in diabetic retinopathy. Mol. Med. Rep. 2015, 12, 4887–4894. [PubMed]
156. Jordan, J.; Fernandez-Gomez, F.J.; Ramos, M.; Ikuta, I.; Aguirre, N.; Galindo, M.F. Minocycline and cytoprotection: Shedding new light on a shadowy controversy. Curr. Drug Deliv. 2007, 4, 225–231. [CrossRef] [PubMed]
157. Moore, K.S.; Wehrli, S.; Roder, H.; Rogers, M.; Forrest, J.N., Jr.; McCrimmon, D.; Zasloff, M. Squalamine: An aminosterol antibiotic from the shark. Proc. Natl. Acad. Sci. USA 1993, 90, 1354–1358. [CrossRef] [PubMed]
158. Ciulla, T.A.; Criswell, M.H.; Danis, R.P.; Williams, J.I.; McLane, M.P.; Holroyd, K.J. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 2003, 23, 808–814. [CrossRef] [PubMed]
159. Higgins, R.D.; Yan, Y.; Geng, Y.; Zasloff, M.; Williams, J.I. Regression of retinopathy by squalamine in a mouse model. Pediatr. Res. 2004, 56, 144–149. [CrossRef] [PubMed]
160. Webster, A.C.; Lee, V.W.; Chapman, J.R.; Craig, J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006, 81, 1234–1248. [CrossRef] [PubMed]
161. Liegl, R.; Koenig, S.; Siedlecki, J.; Haritoglou, C.; Kampik, A.; Kernt, M. Temsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF expression. PLoS ONE 2014, 9, e88203. [CrossRef] [PubMed]
162. Ozdemir, G.; Kilinc, M.; Ergun, Y.; Sahin, E. Rapamycin inhibits oxidative and angiogenic mediators in diabetic retinopathy. Can. J. Ophthalmol. J. Can. D’ophtalmol. 2014, 49, 443–449. [CrossRef] [PubMed]
163. Yagasaki, R.; Nakahara, T.; Ushikubo, H.; Mori, A.; Sakamoto, K.; Ishii, K. Anti-angiogenic effects of mammalian target of rapamycin inhibitors in a mouse model of oxygen-induced retinopathy. Biol. Pharm. Bull. 2014, 37, 1838–1842. [CrossRef] [PubMed]
164. Dugel, P.U.; Blumenkranz, M.S.; Haller, J.A.; Williams, G.A.; Solley, W.A.; Kleinman, D.M.; Naor, J. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology 2012, 119, 124–131. [CrossRef] [PubMed]
165. Seto, B. Rapamycin and mTOR: A serendipitous discovery and implications for breast cancer. Clin. Transl. Med. 2012, 1. [CrossRef] [PubMed]
166. Du, Y.; Veenstra, A.; Palczewski, K.; Kern, T.S. Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc. Natl. Acad. Sci. USA 2013, 110, 16586–16591. [CrossRef] [PubMed]
167. Millen, A.E.; Klein, R.; Folsom, A.R.; Stevens, J.; Palta, M.; Mares, J.A. Relation between intake of vitamins C and E and risk of diabetic retinopathy in the atherosclerosis risk in communities study. Am. J. Clin. Nutr. 2004, 79, 865–873. [PubMed]
168. Lee, C.T.; Gayton, E.L.; Beulens, J.W.; Flanagan, D.W.; Adler, A.I. Micronutrients and diabetic retinopathy a systematic review. Opthalmology 2010, 117, 71–78. [CrossRef] [PubMed]
169. Chous, A.P.; Richer, S.P.; Gerson, J.D.; Kowluru, R.A. The diabetes visual function supplement study (DiVFuSS). Br. J. Ophthalmol. 2016, 100, 227–234. [CrossRef] [PubMed]
170. Akiba, J.; Arzabe, C.W.; Trempe, C.L. Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthalmology 1990, 97, 889–891. [CrossRef]
171. Sebag, J. Vitreous: In Health and Disease, 1st ed.; Springer: New York, NY, USA, 2014.
172. Khoshnevis, M.; Sebag, J. Pharmacologic vitreolysis with ocriplasmin: Rationale for use and therapeutic potential in vitreo-retinal disorders. BioDrugs 2015, 29, 103–112. [CrossRef] [PubMed]
173. Kuppermann, B.D. Ocriplasmin for pharmacologic vitreolysis. Retina 2012, 32, S225–S228; discussion S228–S231. [CrossRef] [PubMed]
174. Haller, J.A.; Stalmans, P.; Benz, M.S.; Gandorfer, A.; Pakola, S.J.; Girach, A.; Kampik, A.; Jaffe, G.J.; Toth, C.A.; Group M.-T.S. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: Subgroup analyses from two randomized trials. Ophthalmology 2015, 122, 117–122. [CrossRef] [PubMed]
175. Varma, R.; Haller, J.A.; Kaiser, P.K. Improvement in Patient-Reported Visual Function after Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release without Surgical Treatment (MIVI-TRUST) Trials. JAMA Ophthalmol. 2015, 133, 997–1004. [CrossRef] [PubMed]
176. Soldi, R.; Mitola, S.; Strasly, M.; Defilippi, P.; Tarone, G.; Bussolino, F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999, 18, 882–892. [CrossRef] [PubMed]
177. Li, Y.J.; Li, X.H.; Wang, L.F.; Kuang, X.; Hang, Z.X.; Deng, Y.; Du, J.R. Therapeutic efficacy of a novel non-peptide alphavbeta3 integrin antagonist for pathological retinal angiogenesis in mice. Exp. Eye Res. 2014, 129, 119–126. [CrossRef] [PubMed]
178. Yoshida, T.; Gong, J.; Xu, Z.; Wei, Y.; Duh, E.J. Inhibition of pathological retinal angiogenesis by the integrin alphavbeta3 antagonist tetraiodothyroacetic acid (tetrac). Exp. Eye Res. 2012, 94, 41–48. [CrossRef] [PubMed]